{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.4","upperLimit":"4.5","value":"0.1"},{"groupId":"OG001","lowerLimit":"-8.5","upperLimit":"1.1","value":"-3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Intent-To-Treat Population includes all participants who are randomized into this study. LS mean and CI are from a repeated measures model on the response variable change from baseline in visual analogue scale.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)","title":"Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score","type":"SECONDARY","unitOfMeasure":"Score on a scale"}